Pfizer asks FDA to approve omicron-specific booster shot
Aug 22, 2022
The drug company says that its new mRNA vaccine produces an immune response against the BA.4 and BA.5 omicron subvariants.
Program that diagnosed fractures virtually led to fewer ER visits for LTC residents: study
By
Alicia Lasek
May 14, 2023
A program that enabled virtual diagnosis and on-site fracture care kept 100% of participating LTC residents out of the emergency department and cut the need for clinic visits, a new study reveals.
Long-term care risks extended negative image without more COVID data from operators: exec
By
James M. Berklan
Jun 16, 2020
Seniors housing and care providers across a wider spectrum must start submitting data to increase transparency about the effects of coronavirus infections, says NIC CEO Brian Jurutka.
Pfizer, BioNTech to pursue 2nd booster shot authorization for older adults
By
Alicia Lasek
Mar 16, 2022
A second booster — or fourth dose — will be necessary to improve the vaccine’s waning protection in the face of omicron, Pfizer’s CEO has stated. Whether the FDA will find the evidence compelling...
Omicron sub-variants cut potency of monoclonal antibodies, mRNA vaccines: study
Mar 04, 2022
Eli Lilly’s bebtelovimab is the only authorized monoclonal antibody that can neutralize all three dominant sub-variants, investigators say.
ADA: Diabetes may quadruple risk for long COVID
Jun 08, 2022
Diabetes may increase the risk for long COVID symptoms fourfold, according to research presented at the annual meeting of the American Diabetes Association.
Test twice? Antigen tests reach peak sensitivity 4 days in, study finds
By
Alicia Lasek (f3)
May 03, 2022
It may be best to repeat an early COVID-19 antigen test a day or two later when symptomatic individuals receive negative results, investigators say.
Study links 3 key risk factors to coronavirus deaths among older adults
By
Alicia Lasek
Mar 10, 2020
The findings could help clinicians better identify high-risk individuals, say investigators.
Senators blast HHS’ restrictive coverage for Alzheimer’s drugs
By
Ron Rajecki
Mar 24, 2023
Health and Human Services Secretary Xavier Becerra came under fire Wednesday during a Senate Finance Committee meeting regarding the Centers for Medicare & Medicaid Services’ restrictive national...
FDA advisers support full approval of Paxlovid for at-risk older adults
By
Alicia Lasek
Mar 16, 2023
The antiviral drug Paxlovid should receive full FDA approval to treat COVID-19 in older adults at risk of severe outcomes, the advisers decided in a Thursday vote.